Got IBD? A Clinical Trial May Be Right for You

A gastroenterologist explains how patients with active inflammatory bowel disease can get early access to newer, potentially better treatments — for free.

7:00 AM

Author | Rene Wisely

Hope is on the horizon for patients with inflammatory bowel disease (IBD), a chronic condition with no cure that requires a lifetime of treatment or surgery to keep in check.

MORE FROM MICHIGAN: Sign up for our weekly newsletter

Multiple clinical trials for a variety of leading-edge medicines are underway at the University of Michigan Inflammatory Bowel Disease Program including six trials that involve drug therapies to target Crohn's disease and ulcerative colitis. Both conditions fall under the IBD umbrella.

The work might prompt IBD patients to ask themselves: Is a clinical trial right for me?

Eligibility and safety

For many, their expectation is that clinical trials are a last resort.

Most clinical trial referrals occur because patients have cycled through most or all existing treatment options and can no longer control their IBD, says gastroenterologist Peter Higgins, M.D., Ph.D., M.Sc., director of the IBD program at U-M.

"They are looking for new options," Higgins says. "A lot of times, they can skip ahead to new generations of medicines that aren't yet approved by the Food and Drug Administration or commercially available but trials are showing they can be safer, more potent and have fewer side effects."

Because clinical trials test the safety and effectiveness of new medicines, patients undergo heightened monitoring. They receive more frequent checks of their vital signs and blood chemistry, and they receive endoscopies more often than traditional IBD patients.

Another benefit: Higgins notes that patients in clinical trials tend to do better overall, which researchers attribute to the heightened care and attention.

Mutual benefits

Clinical trials also can ease a patient's financial burden. Monitoring is free and so is the medication.

SEE ALSO: Mental Health Therapy Can Help IBS, IBD Patients Manage

"These medicines may run $4,000 to $8,000 a month," Higgins says. "If that drug is helping someone to stay in remission, then it's worth it. But it's extremely helpful to get it for free."

Participants also are reimbursed for their travel expenses and parking, he adds, noting that the cost of helping others is priceless.

Because IBD affects only about 1 million people in the United States, finding volunteers for clinical trials can be difficult.

But each one brings researchers a step closer to a cure. And for many patients, clinical trials represent a fast pass to next-generation treatments. Patients can get access to new, better treatments for IBD years before they make it to market. Recently approved IBD medications like Entyvio and Stelara were available to patients in clinical trials more than five years before they were available by prescription.

"A clinical trial is often a good choice for many people with active IBD," Higgins says. "We welcome all volunteers."

To participate in an IBD clinical trial, call (734) 615-4843 or email [email protected].


More Articles About: Digestive Health Inflammatory Bowel Disease (IBD) Crohn's and Colitis Health Care Delivery, Policy and Economics Digestive (GI) Conditions
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories syringes three in a row with one with a shot going into it on a light teal background
Health Lab
TNF inhibitors prevent complications in kids with Crohn’s disease, recommended as first-line therapies
Early treatment of pediatric Crohn’s disease with anti-tumor necrosis factor medications can substantially reduce the risk of perianal fistulas in Crohn’s disease. Michigan Medicine researchers confirmed this finding using prospective data. 
man in pink shirt close up with hand on stomach
Health Lab
Potential culprit identified in lingering Crohn’s disease symptoms
A study from University of Michigan researchers may explain why some patients with Crohn’s disease continue to experience symptoms, even in the absence of inflammation.
out the window woman staring
Health Lab
1 in 3 older adults still experience loneliness and isolation
Rates of loneliness and social isolation in older people have declined from pandemic highs, but are still a problem especially for those with mental or physical health issues or disabilities.
patient looking at paper with provider in scrubs blue in clinic
Health Lab
How race impacts patients’ response to cancer immunotherapy
The first large scale analysis finds immune checkpoint inhibitors are equally effective in Black and white patients, with Black patients having fewer side effects.
On left, a young boy in a wheelchair has his doctor standing to his left and his parent is standing to his right in a show of support. On the right side of the image, the boy is now an adult and is wondering about the cost of his care and if his questions will be answered.
Health Lab
Changing the definition of cerebral palsy
Cerebral palsy is defined as a childhood disorder, which fails to recognize adults living with the condition and the lack of care they receive once they age out of pediatric clinics.
floating AI-type images in red and blues and yellow on blue background
Health Lab
Racial differences in medical testing could introduce bias to AI models
Black patients are less likely than white patients to receive certain medical tests that doctors use to diagnose severe disease, impacting artificial intelligence data. But researchers have found a way to correct the bias in these data sets.